Correlation Between Cabio Biotech and Spero Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cabio Biotech and Spero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cabio Biotech and Spero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cabio Biotech Wuhan and Spero Therapeutics, you can compare the effects of market volatilities on Cabio Biotech and Spero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cabio Biotech with a short position of Spero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cabio Biotech and Spero Therapeutics.

Diversification Opportunities for Cabio Biotech and Spero Therapeutics

-0.63
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Cabio and Spero is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Cabio Biotech Wuhan and Spero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spero Therapeutics and Cabio Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cabio Biotech Wuhan are associated (or correlated) with Spero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spero Therapeutics has no effect on the direction of Cabio Biotech i.e., Cabio Biotech and Spero Therapeutics go up and down completely randomly.

Pair Corralation between Cabio Biotech and Spero Therapeutics

Assuming the 90 days trading horizon Cabio Biotech Wuhan is expected to under-perform the Spero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Cabio Biotech Wuhan is 2.01 times less risky than Spero Therapeutics. The stock trades about -0.17 of its potential returns per unit of risk. The Spero Therapeutics is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  194.00  in Spero Therapeutics on September 10, 2025 and sell it today you would earn a total of  37.00  from holding Spero Therapeutics or generate 19.07% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy92.06%
ValuesDaily Returns

Cabio Biotech Wuhan  vs.  Spero Therapeutics

 Performance 
       Timeline  
Cabio Biotech Wuhan 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Cabio Biotech Wuhan has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors.
Spero Therapeutics 

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Spero Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Spero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Cabio Biotech and Spero Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cabio Biotech and Spero Therapeutics

The main advantage of trading using opposite Cabio Biotech and Spero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cabio Biotech position performs unexpectedly, Spero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will offset losses from the drop in Spero Therapeutics' long position.
The idea behind Cabio Biotech Wuhan and Spero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device